Table 1.
Clinical, pathologic or molecular characteristics according to tumor growth pattern in colorectal cancer
| Tumor growth pattern |
|||||
|---|---|---|---|---|---|
| Clinical, pathologic or molecular feature |
Total N | expansile | intermediate | infiltrative | p value |
| All cases | 1139 | 372 (33%) | 610 (54%) | 157 (14%) | |
| Sex | 0.64 | ||||
| Male | 498 (44%) | 170 (46%) | 260 (43%) | 68 (43%) | |
| Female | 641 (56%) | 202 (54%) | 350 (57%) | 89 (57%) | |
| Mean age ± SD | 68.6 ± 8.9 | 69.0 ± 9.0 | 68.3 ± 8.7 | 68.7 ± 9.5 | 0.43 |
| Family history of colorectal cancer in any first degree relative |
0.74 | ||||
| (−) | 930 (82%) | 307 (83%) | 493 (81%) | 130 (83%) | |
| (+) | 209 (18%) | 65 (17%) | 117 (19%) | 27 (17%) | |
| Year of diagnosis | 0.29 | ||||
| Prior to 1998 | 562 (49%) | 173 (47%) | 314 (51%) | 75 (48%) | |
| 1998-2006 | 577 (51%) | 199 (53%) | 296 (49%) | 82 (52%) | |
| Body mass index (kg/m2) | 0.18 | ||||
| <30 | 924 (81%) | 291 (78%) | 505 (83%) | 128 (82%) | |
| ≤30 | 213 (19%) | 81 (22%) | 104 (17%) | 28 (18%) | |
| Tumor location | 0.18 | ||||
| Proximal colon (cecum to transverse) | 569 (50%) | 174 (47%) | 311 (51%) | 84 (54%) | |
| Distal colon (splenic flexure to sigmoid) |
331 (29%) | 109 (29%) | 185 (30%) | 37 (24%) | |
| Rectum | 233 (21%) | 87 (24%) | 112 (18%) | 34 (22%) | |
| Disease stage | <0.0001 | ||||
| I | 257 (23%) | 144 (39%) | 110 (18%) | 3 (1.9%) | |
| II | 348 (31%) | 111 (30%) | 208 (34%) | 29 (18%) | |
| III | 311 (27%) | 65 (17%) | 190 (31%) | 56 (36%) | |
| IV | 142 (12%) | 23 (6.2%) | 62 (10%) | 57 (36%) | |
| Unknown | 81 (7.1%) | 29 (7.8%) | 40 (6.6%) | 12 (7.6%) | |
| Tumor differentiation | 0.058 | ||||
| Well to moderate | 1025 (90%) | 339 (91%) | 553 (91%) | 133 (85%) | |
| Poor | 114 (10%) | 33 (8.9%) | 57 (9.3%) | 24 (15%) | |
| Mucinous component | 0.017 | ||||
| 0% | 674 (59%) | 202 (54%) | 380 (62%) | 92 (59%) | |
| 1-50% | 337 (30%) | 115 (31%) | 168 (28%) | 54 (34%) | |
| >50% | 128 (11%) | 55 (15%) | 62 (10%) | 11 (7.0%) | |
| Signet ring cell component | 0.0067 | ||||
| 0% | 1008 (89%) | 336 (90%) | 540 (89%) | 132 (84%) | |
| 1-50% | 112 (9.8%) | 32 (8.6%) | 66 (10%) | 17 (11%) | |
| >50% | 19 (1.7%) | 4 (1.1%) | 7 (1.2%) | 8 (5.1%) | |
| Peritumoral lymphocytic reaction | <0.0001 | ||||
| Absent/minimal | 178 (16%) | 36 (9.7%) | 95 (16%) | 47 (30%) | |
| Mild | 782 (69%) | 265 (71%) | 418 (69%) | 99 (63%) | |
| Moderate/marked | 175 (15%) | 70 (19%) | 94 (15%) | 11 (7.0%) | |
| MSI status | 0.0001 | ||||
| MSI-low/MSS | 872 (84%) | 268 (78%) | 467 (84%) | 137 (94%) | |
| MSI-high | 171 (16%) | 74 (22%) | 88 (16%) | 9 (6.2%) | |
| CIMP status | 0.58 | ||||
| CIMP-low/0 | 818 (82%) | 261 (80%) | 446 (83%) | 111 (83%) | |
| CIMP-high | 181 (18%) | 65 (20%) | 93 (17%) | 23 (17%) | |
| KRAS mutation | 0.78 | ||||
| (−) | 671 (64%) | 221 (64%) | 360 (64%) | 90 (61%) | |
| (+) | 380 (36%) | 123 (36%) | 200 (36%) | 57 (39%) | |
| BRAF mutation | 0.076 | ||||
| (−) | 890 (85%) | 291 (84%) | 484 (87%) | 115 (79%) | |
| (+) | 159 (15%) | 55 (16%) | 74 (13%) | 301 (21%) | |
| PIK3CA mutation | 0.93 | ||||
| (−) | 809 (83%) | 265 (83%) | 431 (83%) | 113 (82%) | |
| (+) | 167 (17%) | 53 (17%) | 89 (17%) | 25 (18%) | |
| LINE-1 methylation level (Mean ± SD) |
62.7 ± 9.6 | 62.7 ± 9.5 | 62.4 ± 9.7 | 63.6 ± 9.5 | 0.44 |
(%) indicates the proportion of cases with a specific clinical, pathologic or molecular feature among each expression group. CIMP, CpG island methylator phenotype; MSI, microsatellite instability; MSS, microsatellite stable; SD, standard deviation.